Home / Adel (page 122)

Adel

Johnson & Johnson Posts Strong Q4 Results, Beats Estimates on Robust Cancer Drug Demand

Johnson & Johnson (NYSE:JNJ) reported fourth-quarter earnings and sales that exceeded analysts’ expectations, driven by strong demand for its cancer treatments and contributions from its recent acquisition of Shockwave Medical. Q4 Highlights Revenue: $22.52 billion, a 5.3% year-over-year increase. Adjusted EPS: $2.04 per share, down 11% YoY but above analysts’ …

Read More »